“Approval from the governing ethics board is an important step toward enrolling subjects in the European arm of the AMP-270 clinical trial for locally advanced pancreatic cancer,” stated Prof.
AMP-270 is a randomized, open-label, controlled, parallel-arm clinical trial with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Secondary objectives include comparing safety and tolerability. AMP-270 is expected to enroll approximately 90 subjects in
For more information about AMP-270, please visit ClinicalTrials.gov and reference identifier NCT05494697.
About
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7a656e54-b6f2-4c09-bca2-80267f05c6c4
![](https://ml.globenewswire.com/media/OGRiOWRiNDktZGU0ZC00MDM4LTljMTktNzgyNWFiNTg0NGU4LTEwMzQ3MzU=/tiny/AIM-ImmunoTech-Inc-.png)
Investor Contact:JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
Prof. Casper H.J. van Eijck , MD, PhD
![](https://ml.globenewswire.com/media/7a656e54-b6f2-4c09-bca2-80267f05c6c4/medium/prof-casper-h-j-van-eijck-md-phd.jpg)
Prof. Casper H.J. van Eijck , MD, PhD
2024 GlobeNewswire, Inc., source